Références du Guide d'intervention santé-voyage

  • Andrew M. et al. Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness. In: Wilderness and Environmental Medicine, 21, 146-155 (2010).
  • Bansch P, Maggiorini M, Ritler M, Noti C, Vock P, Oelz O. Prevention of high altitude pulmonary edema by nifedipine. NEJM 1991; 325 : 1284-9.
  • Bates MG. et al. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension double blind, randomized, placebo-controled trial. In: High Alt Med Biol. 2011 Fall; 12 (3): 207-14.
  • Bezruchka S. High altitude medicine. The medical clinics of North America 1992; 76 : 1481-1498.
  • Bezruchka S. Mountaineering activities and high altitude associated disorders. Travel Medicine Advisor : 20.1-20.14.
  • Boussou P. Performance et entraînement en altitude, Aspect physiologique et physiopathologique. Décarie, 1987.
  • Centers for Disease Control and Prevention. CDC Health Information for International Travel 2012. New York: Oxford University Press:2012. Chapter 2: Altitude Illness.
  • Comité consultatif de la médecine tropicale et de la médecine des voyages. Déclaration sur les maladies de haute altitude. Relevé des maladies transmissibles au Canada. Volume 33, DCC 5, 1er avril 2007.
  • Eliswoth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 1991; 154 : 289-293.
  • Hackett P H et Roach R C. High altitude illness. N Engl J Med 2001, 12 juillet : 345-2 : 107-114.
  • Hullgreen H. High altitude medical problems. Scientific American 1990 : 1-13.
  • Hultgren HN. Effects of altitude upon cardiovascular diseases. J Wilderness Med 1992; 3 : 301-308.
  • Kayser B. Acute mountain sickness in western tourists around the Thorong pass (5400 m) in Nepal. J Wilderness Med 1991; 2 : 110-117,140-149.
  • Keystone J S et al. Travel Medicine. Mosby, St-Louis, MO, 2004. p. 363-375.
  • Keystone J S et al. Travel Medicine. Mosby, St-Louis, MO, 2008.
  • Leibson C, Brown M, Thiboteau S, Stevenson D, Vreman H, Cohen Ret al. Neonatal hyperbilirubinemia at high altitude. AJDC 1989; 143 : 983-987.
  • MC Intosh Iain B. High altitude, high risk travel. Travel Medicine International 1989 : 164-167.
  • Montgomery AB, Mills J, Luce JM. Incidence of acute mountain sickness at intermediate altitude. JAMA 1989; 261 : 732-734.
  • Moore LG. Altitude - aggravated illness : Examples from pregnancy and prenatal life. Ann Emerg Med 1987; 16 : 965-973.
  • Oelz O, Maggiorini M, Ritler M, Waber V, Jenni R, Vock Pet al. Niledipine for high altitude pulmenary cedema. Lancet nov. 1989; 25 : 1241-1244.
  • Pollard Andrew J, et al. Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001. High Altitude Medicine and Biology. 2001; vol 2 no 3 : 389-403.
  • Rabold M. High-altitude pulmonary edema : a collective review. Am J Emerg Med 1989; 7 : 426-33.
  • Rabold MB. Dexamethasone for prophylaxis and treatment of acute mountain stickness. J Wilderness Med 1992; 3 : 54-60.
  • Robertson JA et Shlim DR. Treatment of moderate acute mountain sickness with pressurization in a portable hyperbasic (Gamow) Bag. J Wilderness Med 1991; 2 : 268-273.
  • Ruchalet JP et Rathat C. Pathologie et altitude. Paris, Masson, 1991.
  • Sutlon JR. Mountain sickness. Neurologic clinics 1992; 10 : 1015-1030.
  • Swapnil J. Paralikar et Jagdish H. Paralikar. High Altitude Medicine. In: Indian Journal of Occupational and Environmental Medicine. Jan-Apr; 14 (1): 6-12. 2010.
  • Tyukodi. Anton high altitude illness. Emergency Prehospital Medicine, février 1988; 2(4).
  • UIAA. Official standards of the UIAA medical commission. Trekking and expedition medicine. Emergency treatment of acute mountain sickness and high altitude pulmonary oedema. 1993.
  • Ward. Milledge et West. High altitude medicine and physiology. Philadelphie, University of Pennsylvania, 1989.
  • West JB. Acclimatization and tolerance to extreme altitude. J Wilderness. Med 1993; 4 : 17-26.
  • West JB. Limiting factors for exercise at extreme altitudes. Clinical physiology 1990; 10 : 265-272.
  • Wilkerson James DA. Medicine for mountaineering, 3e éd. 1985.
  • Zell SC et Goodman PH. Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med 1988; 148 : 541-545.
  • CDC. Imported dengue–United States, 1996. MMWR 1998 Jul 10; 47(26) : 544-547.
  • CDC. Potential risk for dengue hemorrhagic fever : The isolation of serotype dengue-3 in Mexico. Emerging Infectious Diseases April-June 1996; 2(2).
  • Cire Océan indien. Le point épidémio 2010 : no 46.
  • Direction générale de la protection de la santé – Laboratoire de lutte contre la maladie. Rapports internationaux sur l’activité de la fièvre dengue et de la dengue hémorragique. 26 juin 1998.
  • Duperval R, Frost EH, Artsob H. Dengue fever with hemorrhagic manifestations in travellers returning to Québec from Asia. Can J Infect Dis 1993;4 : 220-222.
  • Fauran P. New epidemiological aspects of dengue. Bull Soc Pathol Exot 1996; 89(2) : 163-4.
  • Fauran P. Prediction and prevention of dengue epidemics. Bull Soc Pathol Exot 1996; 89(2) : 123-6.
  • Franco L, Di Caro A, Carletti F et al. Recent expansion of dengue virus serotype 3 in West Africa. Eurosurveillance 2010; 15 (7)
  • Freedman DO, Weld LH, Kozarsky PE et al. Spectrum of disease and relation to place of exposure among ill returned travellers. New England Journal of Medicine 2006 Jan 12; 354 (2) : 119-130.
  • Gjenero-Margan I, Aleraj B, Krajcar D et al. Autochtonous dengue fever in Croatia, August-September 2010. Eurosurveillance 2011; 16 (9) 1-4.
  • Gubler DJ, Clark GG. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1995 Apr-Jun; 1(2) : 55-7.
  • Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998 Jul; 11(3) : 480-96.
  • Gubler DJ, Kuno G. Dengue fever & dengue hemorrhagic fever. Wallingford (UK), CAB Intl, 1998.
  • Halstead SB, Udomsakdi S, Singharaj P et al. Dengue and chikungunya virus infection in man in Thailand, 1962-64III : clinical, epidemiologic, and virologic observations on disease in non-indigenous white persons. Am J Trop Med Hyg 1969;18 : 984-996.
  • Janisch T, Preiser W, Berger A, Niedrig M, Mikulicz U, Thoma B, Doerr HW. Emerging viral pathogens in long-term expatriate(II) : Dengue virus. Trop Med Int Health 1997 Oct; 2(10) : 934-40.
  • Jelinek T. Dengue fever in international travelers. Clin Infect Dis 2000; 31 : 144-147.
  • Jelinek T, Dobler G, Holscher M, Loscher T, Nothdurft HD. Prevalence of infection with dengue virus among international travelers. Arch Intern Med 1997 Nov 10; 157(20) : 2367-70.
  • Jelinek T, Muhlberger N, Harms G et al. Epidemiology and clinical features of imported dengue fever in Europe: Sentinel surveillance data from TropNetEurop. Clin Infect Dis 2002; 35 : 1047-1052.
  • Jetten TH, Focks DA. Potential changes in the distribution of dengue transmission under climate warming. Am J Trop Med Hyg 1997 Sep; 57(3) : 285-97.
  • Karp BE. Dengue fever: a risk to travelers. Md Med J 1997 Jul; 46(6) : 299-302.
  • Lancet. Editorial Dengue in the Americas–time to talk. Lancet 1997 Aug 16; 350(9076) : 455.
  • Lange WR, Beall B, Denney SC. Dengue fever: a resurgent risk for the international traveler. Am Fam Physician 1992;45 : 1161-1168.
  • La Ruche G, Souarès Y, Armengaud A et al. First two autochtonous dengue virus infections in metropolitan France, September 2010. Eurosurveillance 2010; 15 (39) 1-5.
  • Lindbäck H, Lindbäck J, Tegnell A et al. Dengue fever in travelers to the tropics, 1998 and 1999. Emerg Infect Dis 2003;9 : 438-442.
  • McBride WJ, Mullner H, LaBrooy JT, Wronski I. The 1993 dengue-2 epidemic in Charters Towers, North Queensland : clinical features and public health impact. Epidemiol Infect 1998 Aug; 121(1) : 151-6.
  • Mondet B, da Rosa AP, Vasconcelos PF. The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus. Bull Soc Pathol Exot 1996; 89(2) : 107-13.
  • OMS. Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control. Genève, OMS, 1997.
  • Ostroff SM, Kozarsky P. Emerging infectious diseases and travel medicine. Infect Dis Clin North Am 1998 Mar; 12(1) : 231-41.
  • PAHO. Dengue and dengue hemorrhagic fever, 1996. Epidemiol Bull 1996 Dec; 17(4) : 12-4.
  • PAHO/WHO Communicable diseases program. Population at risk and incidence of dengue and dengue hemorrhagic fever (DHF) in the Americas - 1995. PAHO.
  • Phoutrides EK, Coulibaly MB, George CM et al. Dengue virus seroprevalence amonf febrile patients in Bamako, Mali : results of a 2006 surveillance study. Vector borne zoonotic diseases 2011; 11 (11) 1479-85.
  • Pinheiro FP, Corber SJ. Global situation of dengue and dengue haemorrhagic fever, and its emergence in the Americas. World Health Stat Q 1997; 50 (3-4) : 161-9.
  • Reynes JM. Dengue in French Guiana. History and present status. Bull Soc Pathol Exot 1996; 89(2) : 98-100.
  • Rigau-Pérez JG, Clark GG, Gubler DJ et al. Dengue and dengue haemorrhagic fever. Lancet 1998;352 : 971-977.
  • Rigau-Perez JG, Gubler DJ, Vorndam AV, Clark GG. Dengue: A literature review and case study of travelers from the United States, 1986-1994. Travel Med 1997 Jun 1; 4(2) : 65-71.
  • Rodhain F. The situation of dengue in the world. Bull Soc Pathol Exot 1996; 89 (2): 87-90.
  • Rosen L. Dengue hemorrhagic fever. Bull Soc Pathol Exot 1996; 89 (2) : 91-3.
  • Rossi CA, Drabick JJ, Gambel JM, Sun W, Lewis TE, Henchal EA. Laboratory diagnosis of acute dengue fever during the United Nations mission in Haiti, 1995-1996. Am J Trop Med Hyg 1998 Aug; 59(2) : 275-8.
  • Santé Canada. Recommandation relative aux voyages : Dengue et voyages internationaux. RCMT 1996; 22 : 25-28.
  • Savage HM, Fritz CL, Rutstein D, Yolwa A, Vorndam V, Gubler DJ. Epidemic of dengue-4 virus in Yap State, Federated States of Micronesia, and implication of Aedes hensilli as an epidemic vector. Am J Trop Med Hyg 1998 Apr; 58(4) : 519-24.
  • Sharp TW, Wallace MR, Hayes CG et al. Dengue fever in U.S. troops during Operation Restore Hope, Somalia, 1992-1993. Am J Trop Med Hyg 1995;53 :89-94.
  • Shirtcliffe P, Cameron E, Nicholson KG, Wiselka MJ. Don’t forget dengue! Clinical features of dengue fever in returning travellers. J R Coll Physicians Lond 1998 May-Jun; 32(3) : 235-7.
  • Tolou H, Baudon D, Laroche R. Current status of dengue virus infections. Epidemiologic and pathogenetic aspects. Med Trop (Mars) 1997; 57(1) : 71-6.
  • Tolou H, Durand JP, Pisano MR. Current status of dengue, Med Trop (Mars) 1997; 57(3 Suppl) : 70-3.
  • Trofa AF, DeFraites RF, Smoak BL, Kanesa-thasan N, King AD, Burrous JM, MacArthy PO, Rossi C, Hoke CH Jr. Dengue fever in US military personnel in Haiti. JAMA 1997 May 21; 277(19) : 1546-8.
  • Von Zielonka M. Risques infectieux et voyages. Pradel, Paris, 1992.
  • Wichmann O, Gascon J, Schunk M et al. Sever dengue virus infection in travellers: risk factors and laboratory indicators. Journal of Infectious Diseases 2007 Apr 15; 195 : 1089-96.
  • Yebakima A. Control of Aedes aegypti in Martinique. Contribution of entomology studies. Bull Soc Pathol Exot 1996; 89(2) : 161-2.

Références pour la mise à jour de février 2017 :

Références des éditions antérieures :

  • Adachi JA et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. CID 2003; 37 : 1165-71.
  • Adachi JA et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infec Dis 2001; 32 : 1706-1709.
  • Bierer DW. Bismuth subsalicylate : history, chemistry, and safety. Rev Infect Dis. 1990;12 Suppl 1 : S3-8.
  • BRIGGS, Gerald G.; FREEMAN, Roger K, Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk », 10 th edition, 2015
  • Centers for Disease Control and Prevention. Managing acute gastroenteritis among children : oral rehydration, maintenance, and nutritional therapy. MMWR 2003; 52(No. RR-16) : 1-16.
  • CDC Yellow book, 2014
  • Cheng AC et Thielman NM. Update on traveler’s diarrhea. Curr Infect Dis Rep 2002; 4 : 70-77.
  • Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Déclaration sur la diarrhée du voyageur. Relevé des maladies transmissibles au Canada. Vol 27 DCC-3. 15 mars 2001.
  • CONNOR, BA. « Traveler's diarrhea. The Yellow Book », Centers for Disease Control Health Information for International Travel.
  • Déclaration sur la diarrhée du voyageur. Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Agence de la santé publique du Canada. Avril 2015
  • Déclaration sur le nouveau vaccin oral contre le choléra et la diarrhée du voyageur. Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV) et Comité consultatif national de l’immunisation (CCNI). RMTC. Volume 31. DCC-7. 1 juillet 2005 http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/05vol31/asc-dcc-7/index-fra.php
  • Ericsson CD et Johnson PC. Safety and efficacy of loperamide. Am J Med 1990; 88 : 10S-14S.
  • Ericsson CD. Nonantimicrobial agents in the prevention and treatment of traveler’s diarrhea. Clin Infect Dis 2005; 41 Suppl 8 : S557-563.
  • GINEFRI, Lauriane et Ema FERREIRA. « La diarrhée », [auteure du livre] E. Ferreira, B. Martin et C. Morin. Grossesse et allaitement Guide thérapeutique, Montréal : CHU Sainte-Justine, 2e édition, 2013, chapitre 19, pp. 438-447.
  • GINEFRI, Lauriane et Caroline MORIN. « Anti-infectieux durant l'allaitement », [auteure du livre] E. Ferreira, B. Martin et C. Morin. Grossesse et allaitement Guide thérapeutique, Montréal : CHU Sainte-Justine, 2e édition, 2013, chapitre 29, pp. 641-671.
  • Gouvernement du Canada, Solutions de réhydratation orale, http://www.voyage.gc.ca/voyager/sante-securite/rehydratation
  • Hill DR. Occurrence and self-treatment of diarrhea in a large cohort of Americans traveling to developing countries. Am J Trop Med Hyg 2000; 62 : 585-589.
  • Hill, David et collab. Oral cholera vaccines: use in clinical practice. http://infection.thelancet.com Vol 6 June 2006
  • KOO Hoonmo. DUPONT Herbert et HUANG David. Therapeutics and Clinical Risk Management. The role of rifaximin in the treatment and chemoprophylaxis of travelers’ diarrhea. Dovepress. October 2009
  • Lexicomp Clinical Drug  Information 2016 : en ligne http://www.wolterskluwercdi.com/lexicomp-online/
  • Loscher T et Connor BA. Clinical presentation and treatment of travelers’ diarrhea. In : Keystone JS et al. dir. de la réd. Travel medicine. St Louis Mo, Mosby, 2004, 175-199.
  • Ministère de la Santé et des Services sociaux, Protocole d’immunisation du Québec Section 10.6.1 Chol-Ecol-O : vaccin oral contre le choléra et la diarrhée à ETEC, http://publications.msss.gouv.qc.ca/msss/fichiers/piq/chap10-6-1.pdf
  • Peltola H et al. Prevention of travellers’ diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338 : 1285-1289.
  • Rashed Selim et collab. Médecine tropicale, santé internationale et santé de l’enfant immigrant.. Éditions santé internationale. 2007
  • Rendi-Wagner P and Kollaritsch H. Drug prophylaxis for travelers’ diarrhea. CID 2002; 34 : 628-33.
  • Résumé de la Déclaration sur la diarrhée du voyageur. Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Agence de la santé publique du Canada. Novembre 2015
  • Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE. 2012;7(4).
  • RMTC-Déclaration du CCMTMV sur la diarrhée du voyageur Vol. 27 (ACS-3)/(DCC-3) 15 mars 2001 http://www.collectionscanada.gc.ca/webarchives/20071124190633/http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/01pdf/acs27-3.pdf
  • Robins-Browne RM and Hartland EL. Escherichia coli as a cause of diarrhea. J Gastroenterol Hepatol 2002; 17 : 467-75.
  • Sanford guide to antimicrobial therapy 2016, 46 th edition : http://webedition.sanfordguide.com/
  • Shah, Nipam et autres. Global Etiology of Travellers’Diarrhea : Systematic Review from 1973 to the Present. Am. J. Trop. Med. Hyg 80(4), 2009, pp 609-614
  • Steffen R et al. Epidemiology, etiology and impact of traveler’s diarrhea in Jamaica. JAMA 1999; 281 : 811-817.
  • Steffen R. Epidemiology of traveler’s diarrhea. Clin Infect Dis 2005; 41 Suppl 8 : S536-540.
  • Sullivan Å, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med. 2005;257(1):78–92.
  • The medical letter. Volume 46 (Issue 1191) September 13, 2004. Rifaximin (Xifaxan) for travellers.
  • Thielman NM et Guerrant RL. Acute infectious diarrhea. NEJM 2004; 350 : 38-47.
  • Vargas M et al. Prevalence of diarrheagenic Escherichia coli strains detected by PCR in patients with travelers’ diarrhea. Clin Microbiol Infect 1998; 4 : 682- 688.
  • Backer H. Field water disinfection. Dans : Averbach P. ed. Wilderness medicine, 4e edition, St-Louis, MO : 2001 : 1186-1236.
  • Backer H, Hollowell J. Use of iodine for water disinfection : Iodine toxicity and maximum recommended dose. Environ Health Perspect 2000; 108 : 679-684.
  • Backer H. Water disinfection for International Travelers. Dans : Keystone J. Travel Medicine, 1ère edition. Mosby, St-Louis, MO, 2004 : 49-59.
  • Bandres J, Mathewson J., DuPont H. Heat susceptibility of bacterial enteropathogens. Arch Intern Med 1988; 148 : 2261-2263.
  • Gerba C, Naranjo J. Microbiological water purification without the use of chemical disinfection. Wilderness Environ Med 1999; 10 : 12-16.
  • US environmental Protection Agency. Guide standard and protocol for testing microbiological water purifiers. Report to Task Force. Cincinnati : US environmental Protection Agency; 1987.

Références pour la mise à jour de juin 2018

Références antérieures

  • Ayukawa R, Fujimoto H, Ayabe M et al. An unexpected outbreak of Japanese encephalitis in the Chugoku district of Japan, 2002. Jpn J Infect Dis 2004; 57 : 63-66.
  • Buhl MR, Black FT, Andersen PL, Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scant J Infect Dis 1996; 28 : 189.
  • Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV). Déclaration sur le vaccin contre l’encéphalite japonaise. RMTC 1998 : 24.
  • Igarashi A, Tanaka M, Morita K et al. Detection of west Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol Immunol 1994; 38(10) : 827-830.
  • Japanese encephalitis on the Australian mainland. Comm Dis Intell 1998 May 14; 22(5).
  • Johansen C et al. The search for Japanese encephalitis virus in the western province of Papua New Guinea, 1996. Arbovirus Res Aust 1997; 7 : 131-136.
  • Konishi E, Shoda M, Kondo T. Prevalence of antibody to Japanese encephalitis virus non-structural protein among racehorses in Japan: indication of natural infection and need for continuous vaccination. Vaccine 2004; 22 : 1097-1103.
  • Konishi E, Suzuki T. Ratios of subclimical Japanese encephalitis (JE) virus infections in vaccined populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations. Vaccine 2002; 21 : 98-107.
  • Lam K, Tsang OTY, Yung RWH, Lau KK. Japanese encephalitis in Hong Kong. Hong Kong Med J 2005; 11 : 182-188.
  • Mackenzie JS, Broom AK, Hall RA et al. Arbovirus in the Australian region, 1990 to 1998. Comm Dis Intell 1998; 22 : 93-100.
  • Mackenzie JS et al. Emergence of Japanese encephalitis virus in the Australian region. In Saluzzo JF, Doded B, dir. de la rédaction. Factors in the emergence of arbovirus diseases. Paris, Elsevier, 1997; 191-201.
  • Mackenzie JS. Japanese encephalitis : an emerging disease in the Australian region and its potential risk to Australia. Arbovirus Res Aust 1997; 7 : 166-170.
  • Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers : exploring the limits of risk. Clin Infect Dis 2002; 35 : 183-188.
  • Spicer PE. Japanese encephalitis in Western Irian Jaya. J Travel Med 1997; 4 : 146-147.
  • Wittesjö B, Eitrem R, Niklasson B et al. Japanese encephalitis after a 10-day holiday in Bali. Lancet 1995; 345 : 856.
  • CDC. Updates U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR 2005;54(RR-9).
  • Smith, D.K.,  Grohskopf, L.A.,  Black, R.J., et collab. (2005) Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep, 54(RR-2), 1-20. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm
  • Panlilio, A.L.,  Cardo, D.M.,  Grohskopf, L.A., et collab. (2005) Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep, 54(RR-9), 1-17. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5409a1.htm
  • Fiore, A.E., Shay, D.K., Broder, K., et collab. (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep, 57(RR-7), 1-60. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5707a1.htm
  • Bruneau, A.,  Baril, J.G.,  Dupont, M., et collab. (2011) Guide pour la prophylaxie postexposition (PPE) à des liquides biologiques dans le contexte du travail, Ministère de la Santé et des Services sociaux, 65 p. http://publications.msss.gouv.qc.ca/msss/document-000582/
  • Kuhar, D.T.,  Henderson, D.K.,  Struble, K.A., et collab. (2013) Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol, 34(9), 875-92. http://stacks.cdc.gov/view/cdc/20711
  • AIDSinfo -  Offering information on HIV/AIDS Treatment, Prevention, and Research  https://aidsinfo.nih.gov/
  • Guide thérapeutique VIH/VHC, Feuillets des antirétroviraux, http://www.guidetherapeutiquevih.com/feuillets-antiretroviraux.asp
  • The University of Liverpool, http://www.hiv-druginteractions.org/
  • Background Consultation on Yellow Fever and International Travel 2010 (update February 2011). Informal Working Group on Geographic Risk of Yellow Fever. http://www.who.int/ith/YFrisk.pdf.
  • CDC. Fever, jaundice, and multiple organ system failure assiciated with 17D-derived yellow fever vaccination, 1996-2001. MMWR 2001; 50(30) : 643-645.
  • CDC Health Information for International Travel. Centers for Disease Control 2012, Atlanta. http://wwwnc.cdc.gov/travel/page/yellowbook-2012-home.htm.
  • Cetron M. New data on adverse effects of yellow fever vaccine. Rapport de la 8e conférence de l’ISTM, New York, 2003. (SY09.01).
  • Chastel C. Reflection on 2 current viral diseases : yellow fever and dengue. Ann Biol Clin (Paris) 1997 Sep-Oct; 55(5) : 415-24.
  • Country list: 2017 updates in English, 2016 updates in other languages http://www.who.int/ith/2017-ith-country-list.pdf?ua=1
  • Déclaration sur la fièvre jaune à l’intention des voyageurs. Comité consultatif de la médecine tropicale et de la médecine des voyages, Relevé des maladies transmissibles au Canada, octobre 2010, vol. 36, DCC-11. http://www.phacaspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-11/pdf/yf-fj.p….
  • Fontenille D, Diallo M, Mondo M, Ndiaye M, Thonnon J. First evidence of natural vertical transmission of yellow fever virus in Aedes aegypti, its epidemic vector. Trans R Soc Trop Med Hyg 1997 Sep-Oct; 91(5) : 533-5.
  • Foster KR, Jenkins MF, Toogood AC. The Philadelphia yellow fever epidemic of 1793. Sci Amer 1998 Aug; 279(2) : 88-93.
  • International travel and Health, 2012 Edition, Genève. http://www.who.int/ith/en
  • Keystone JS, Dismukes R, Sawyer L, Kozarsky PE. Inadequacies in health recommendations provided for international travelers by North American travel health advisors. J Travel Med 1994 Jun 1; 1(2) : 72-78.
  • Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination : a report of four cases. Lancet 2001; 358 : 98-104.
  • Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS and the GeoSentinel yellow fever working group. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7(6) : 945-951.
  • McFarland JM, Baddour LM, Nelson JE, Elkins SK, Craven RB, Cropp BC, Chang GJ, Grindstaff AD, Craig AS, Smith RJ. Imported yellow fever in a United States citizen. Clin Infect Dis 1997 Nov; 25(5) : 1143-7.
  • Ministerio da Saude (Ministère de la santé du Brésil). FUNASA. Febre amarela silvestre. Boletim eletronico epidemiologico 2001; 1(1) : 4. http://www.funasa.gov.br/pub/pub00.htm#.
  • Monath TP, Cetron MS. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002; 34 : 1369-1378.
  • Nishioka S de A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL. Yellow fever vaccination during pregnancy and spontaneous abortion : a case-control study. Trop Med Int Health 1998 Jan; 3(1) : 29-33.
  • OMS. Fièvre jaune. Réunion technique de consensus, Genève, 2-3 mars 1998. Genève, OMS, 1999.
  • OMS. International travel and health. Country list. Vaccination requirements and malaria situation. http://www.who.int/ith/countries/en/ . Accès le 11 août 2006.
  • OMS. (2022). Mise à jour sur la fièvre jaune dans le monde, 2021. Relevé épidémiologique hebdomadaire, 97(32), 365-380. https://apps.who.int/iris/handle/10665/361614
  • OMS. (2022). Yellow fever – East, West, and Central Africa. Disease Outbreak News. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON405 
  • PAHO. (2022). Epidemiological Alert: Yellow Fever – 31 August 2022. https://www.paho.org/en/documents/epidemiological-alert-yellow-fever-31-august-2022#:~:text=In%20the%20Region%20of%20the,of%20varying%20magnitudes%20is%20high
  • Sanders EJ, Marfin AA, Tukei PM, Kuria G, Ademba G, Agata NN, Ouma JO, Cropp CB, Karabatsos N, Reiter P, Moore PS, Gubler DJ. First recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. Am J Trop Med Hyg 1998 Oct; 59(4) : 644-9.
  • Temporary Yellow Fever vaccination requirements for International Travellers related to current outbreaks in Africa, WHO. http://www.who.int/ith/updates/20160725/en/. Accès 28 juillet 2016.
  • The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Jentes ES et al., for the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. Août 2011, n° 11, vol. 8, p 622-632.
  • Tolou H, Pisano MR, Durand JP. Molecular epidemiology of yellow fever, Med Trop (Mars) 1998; 58 (2 Suppl) : 37-41.
  • Voyages internationaux et santé. Organisation mondiale de la santé 2011, Genève. http://www.who.int/ith/fr/index.html.
  • Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 30 juillet 2010, vol. 59, no RR—7, pp. 1 – 27. http://www.cdc.gov/mmwr/pdf/rr/rr5907.pdf.
  • Agboatwalla M, Isomura S, Miyake K, Yamashita T, Morishita T, Akram DS. Hepatitis A, B and C seroprevalence in Pakistan. Indian J Pediatr 1994 Sep-Oct; 61 (5) : 545-9.
  • Anis E, Leventhal A, Roitman M, Slater PE. Introduction of routine hepatitis A immunization in Israel - the first in the world. Dept. of Epidemiology and Public Health Services, Israel Ministry of Health, Jerusalem. Harefuah 2000 Feb 1;138(3) : 177-80, 272.
  • Barros H, Oliveira F, Miranda H. A survey on hepatitis A in Portuguese children and adolescents. J Viral Hepat 1999 May; 6(3) : 249-53.
  • Beran J, Douda P, Rychly R. Seroprevalence of viral hepatitis A in the Czech Republic. Eur J Epidemiol 1999 Oct;15(9) : 805-8.
  • Brown MG, Lindo JF, King SD. Investigations of the epidemiology of infections with hepatitis A virus in Jamaica. Ann Trop Med Parasitol 2000 Jul;94(5) : 497-502.
  • Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine 2000 Feb 18;18 Suppl 1(4) : S68-70.
  • Comité consultatif national de l’immunisation (CCNI). Déclaration supplémentaire sur la prévention de l’hépatite A. RMTC 1996; 22 (1) : 1-3.
  • Comité consultatif national de l’immunisation (CCNI). Déclaration relative à la prévention de l’hépatite A. RMTC 1994; 20 (16) : 133-143.
  • Dalekos GN et al. Prevalence of viral markers among refugees from southern Albania : increased incidence of infection with hepatitis A, B and D viruses. Eur J Gastroenterol Hepatol 1995 juin; 7 (6) : 553-8.
  • Da Villa G, Andjaparidze A, Cauletti M, Franco E, Roggendorf M, Sepe A, Zaratti L. Viral hepatitis in the Bhutanese population : preliminary results of a seroepidemiological investigation. Res Virol 1997 Mar-Apr; 148 (2) : 115-7.
  • Dowe G, King SD, Smikle MF, Wynter HH, Chout R, Klaskala W. Prevalence of viral and bacterial sexually transmitted pathogens in Jamaican pregnant women. West Indian Med J 1998 Mar; 47 (1) : 23-5.
  • Dulat C, Defrance JP, Ille H. Statut immunologique des militaires d’origine antillaise vis-à-vis du virus de l’hépatite A : incidence sur la prophylaxie. Med Trop (Mars) 1996;56(3) : 255-8.
  • Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996 Oct; 117 (2) : 313-25.
  • FitzSimons D, Van Damme P. Prevention and control of hepatitis B in central and eastern Europe and the Newly Independent States, Siofok, Hungary, 6-9 October 1996. Vaccine 1997; 15 (15) : 1595-7.
  • Fock KM et al. Seroprevalence of antibodies agains hepatitis A (anti-HAV) in Singapore : the NFDD experience. Singapore Med J 1995 fév.; 36 (1) : 26-7.
  • Gdalevich M, Grotto I, Mandel Y, Mimouni D, Shemer J, Ashkenazi I. Hepatitis A antibody prevalence among young adults in Israel - the decline continues. Epidemiol Infect 1998 Oct; 121 (2) : 477-9.
  • Green MS, Aharonowitz G, Shohat T, Levine R, Anis E, Slater PE. The changing epidemiology of viral hepatitis A in Israel. Isr Med Assoc J 2001 May;3(5) : 347-51
  • Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38 Suppl 2 : S18-23.
  • Hadjipanayis A, Hadjichristodoulou C, Kallias M, Sava K, Petsa A, Demetriadou K, Christodoulou C, Constantinou A, Sidera M. Prevalence of antibodies to hepatitis A among children and adolescents in Larnaca area, Cyprus. Eur J Epidemiol 1999 Nov;15(10) : 903-5.
  • Hernandez F, Monge R, Jimenez C, Taylor L. Rotavirus and hepatitis A virus in market lettuce (Latuca sativa) in Costa Rica. Int J Food Microbiol 1997 Jul 22; 37 (2-3) : 221-3.
  • Howitz M, Mazick A, Mølbak K. Hepatitis A outbreak in a group of Danish tourists returning from Turkey, October 2005. Eurosurveillance Weekly December 1, 2005. 12(12). http://www.eurosurveillance.org/ew/2005/051201.asp#2
  • Irshad M, Joshi YK, Acharya SK, Tandon BN. Prevalence of hepatitis B virus infection in healthy persons in North India. Natl Med J India 1994 Sep-Oct; 7 (5) : 210-2.
  • Jong EC. Immunizations for international travel. Infectious Disease Clinics of North America juin 1998; 12 (2) : 249-266.
  • Larouzé B, Bouchaud O, Dazza MC, Samb B. Prévention des hépatites virales chez les voyageurs et les expatriés en milieu tropical et subtropical. Rev Épidém et Santé Publ 1998; 46 : 56-62.
  • Lionis C, Frangoulis E, Koulentakis M, Biziagos E, Kouroumalis E. Prevalence of hepatitis A, B, and C markers in school children of a rural area of Crete, Greece. Eur J Epidemiol 1997 Jun; 13 (4) : 417-20.
  • Lonergan G. Epidemiology of hepatitis A in Montreal travelers. 5th International Conference on Travel Medicine, 24-27 mars 1997, Genève.
  • Malamitsi-Puchner A et al. Prevalence study of different hepatitis markers among pregnant Albanian refugees in Greece. Eur J Epidemiol juin 1996; 12 (3) : 297-301.
  • Marinho RT, Valente AR, Ramalho FJ, de Moura MC. The changing epidemiological pattern of hepatitis A in Lisbon, Portugal. Eur J Gastroenterol Hepatol. 1997 Aug;9(8) : 795-7.
  • Mazokopakis E, Vlachonikolis J, Philalithis A, Lionis C. Seroprevalence of hepatitis A, B and C markers in Greek warship personnel. Eur J Epidemiol 2000;16(11) : 1069-1072
  • Mittal SK, Rao S, Rastogi A, Aggarwal V, Kumari S. Hepatitis B – potential of perinatal transmission in India. Trop Gastroenterol 1996 Jul-Sep; 17 (3) : 190-2.
  • Paquet C et al. Viral hepatitis in Bucharest. Bull World Health Organ 1993; 71 (6) : 781-6.
  • Perez OM, Morales W, Paniagua M, Strannegard O. Prevalence of antibodies to hepatitis A, B, C, and E viruses in a healthy population in Leon, Nicaragua. Am J Trop Med Hyg 1996 Jul; 55 (1) : 17-21.
  • Polz-Dacewicz MA, Policzkiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection – a comparative study in central eastern Poland (1990-1999). Med Sci Monit 2000 Sep-Oct;6(5) : 989-93.
  • Rumi MA, Begum K, Hassan MS, Hasan SM, Azam MG, Hasan KN, Shirin M, Khan AK. Detection of hepatitis B surface antigen in pregnant women attending a public hospital for delivery : implication for vaccination strategy in Bangladesh. Am J Trop Med Hyg 1998 Aug; 59 (2) : 318-22.
  • Schmunis GA, Zicker F, Pinheiro F, Brandling-Bennett D. Risk for transfusiontransmitted infectious diseases in Central and South America. Emerg Infect Dis 1998 Jan-Mar; 4 (1) : 5-11.
  • Sikorska K et al. An epidemiologic assessment of viral hepatitis type A morbidity in the Gdansk province in the years 1989-1990. Przegl Epidemiol 1993; 47 (3) : 225-33.
  • Smikle M, Dowe G, Hylton-Kong T, Williams E. Hepatitis B and C viruses and sexually transmitted disease patients in Jamaica. Sex Transm Infect 2001 Aug;77(4) : 295-296.
  • Steffen R. et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994; 272 (11) : 885-9.
  • Steffen R. Epidemiologic basis for the practice of travel medicine. J Wilderness Med 1994; 5 : 56-66.
  • Steffen R. Hepatitis A and hepatitis B : risks compared with other vaccine preventable diseases and immunization recommendations. Vaccine 1993; 11 (5) : 518-20.
  • Steffen R. Immunization against hepatitis A and hepatitis B infections. J Travel Med 2001; 8(Suppl 1) : S9-S16
  • Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, Van Damme P. Epidemiology and prevention of hepatits A in travelers. JAMA 1994; 271 : 885-889.
  • Stroffolini T, Mele A, Tosti ME, Gallo G, Balocchini E, Ragni P, Santonastasi F, Marzolini A, Ciccozzi M, Moiraghi A. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000 Dec; 33(6) : 980-5.
  • Tandon BN, Acharya SK, Tandon A. Epidemiology of hepatitis B virus infection in India. Gut 1996; 38 Suppl 2 : S56-9.
  • Tufenkeji H. Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine. 2000 Feb 18;18 Suppl 1 : S65-7.
  • Viel JF, Fest T, Dussaucy A, Pobel D, Agis F. Hepatitis B virus infection on a tropical island : sociodemographic and geographic risk factors in Guadeloupe. Am J Trop Med Hyg 1995 May; 52 (5) : 398-402.
  • Withers BG, Kelley PW, Pang LW, Kustermann JA, MacArthy PO, Russell BJ, Pallansch MA. Vaccine-preventable disease susceptibility in a young adult Micronesian population. Southeast Asian J Trop Med Public Health 1994 Sep; 25 (3) : 569-74.
  • Wong DC, Purcell RH, Rosen L. Prevalence of antibody to hepatitis A and hepatitis B viruses in selected populations of the South Pacific. Am J Epidemiol 1979 Sep; 110 (3) : 227-36.
  • Freedman DO, Leder K. Influenza : changing approaches to prevention and treatment in travellers. Journal of Travel Medicine 2005; 12 : 36-44.
  • Santé Canada, Agence de santé publique du Canada : surveillance de l’influenza. http://www.phac-aspc.gc.ca/fluwatch/index_f.html .
  • Santé Canada, Comité consultatif de la médecine tropicale et de la médecine des voyages (CCMTMV), Comité consultatif national de l’immunisation (CCNI). Voyages, grippe et prévention. RMTC 1er septembre 1996; 22(17).
  • Santé Canada, Comité consultatif national de l’immunisation (CCNI). Déclaration sur la vaccination anti-grippale pour la saison 2004-2005. RMTC 15 juin 2004; 30 : DCC-3.
  • Santé Canada, Programme de médecine des voyages. Grippe et voyages : bateaux de croisière et voyages organisés par voie de terre. 6 juin 2000. http://www.hc-sc.gc.ca/pphb-dgspsp/tmp-pmv/2000/cruzpr_f.html .
  • Santé Canada, Programme de médecine des voyages, conseils de santé aux voyageurs : Influenza aviaire A (H5N1) : activité chez les humains en Asie. Mise à jour 3 février 2005. http://www.phac-aspc.gc.ca/tmp-pmv/2005/h5n1050203_f.html.
  • Steffen R, Connor BA. Vaccines in travel health : from risk assessment to priorities. Journal of Travel Medicine 2005; 12 : 26-35.

Nouvelles références pour 2016:

Nouvelles références pour 2015 :

Références des éditions antérieures

  • Abou-Donia MB et al. Neurotoxicity resulting from coexposure to pyridostigmine bromide, deet and permethrin : implications of Gulf War chemical exposures. J Toxicol Environ Health, mai 1996; 48(1) : 35-56.
  • Aylward JM. Hydrochloroquine and chloroquine : assessing the risk of retinal toxicity, J Am Optom Assoc, novembre 1993; 64(11) : 787-97.
  • Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004 : 39; 1335-45.
  • Baird JK. Chloroquine resistance in Plasmodium vivax. AAC 2004 : 48; 4075-83.
  • Balo KP et al. Chloroquine maculopathy and prevention of malaria. J Fr Ophtalmol 1996; 19(12) : 770-6.
  • Bartel PR et al. Visual function and long-term chloroquine treatment. S Afr Med J, janvier 1994; 84(1) : 32-4.
  • Boggild AK, Parise ME, Lewis LS, Kain KC. Atovaquone-proguanil : report from the CDC expert meeting on malaria chemoprophylaxis (2). American journal of tropical medicine and hygiene 2007, 76 (2) : 208-23.
  • Boudreau E et al. Tolerability of prophylatic Lariam regimens. Trop Med and Parisitol, septembre 1993; 44(3) : 257-65.
  • Brown M, Hebert AA. Insect repellents an overview. Journal of American Academic Dermatology, février 1997; 36 (2PT1) : 243-9.
  • Cox NH, Paterson WD. Ocular toxicity of antimalarials in dermatology : a survey of current practice. Br J Dermatol, Décembre 1994; 131(6) : 878-82.
  • Durrheim DN et al. Accurary of a rapid immunochromatographic card test for Plasmodium falciparum in a malaria control programme in South Africa. Transactions of the Royal Society of Tropical Medicine 1998; 92 : 32-33.
  • Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347(1) : 13-18.
  • Fryauff DJ et al. Malaria in a non immune population after extended chloroquine or primaquine prophylaxis, Am J Trop Med Hyg, février 1997, 56(2) : 137-40.
  • Garner P, Brabin B. A review of randomized controlled trials of routine antimalarial drug prophylaxis during pregnancy in endemic malarious areas. Bull OMS 1994; 72(1) : 89-99.
  • GlaxoSmithKline Inc. Monographie du Malarone®. Mississauga, GlaxoSmithKline Inc. 2001 (revision 2002), 39 pages.
  • Goodman and Gilman’s. The pharmacological basis of therapeutics, 9e éd. McGraw-Hill, 1996, 1905 pages.
  • Goodyer L, Behrens RH. Short report : the safety and toxicity of insect repellents. Am J Trop Med Hyg 1998; 59(2) : 323-324.
  • Grierson DJ. Hydrochloroquine and visual screening in a rheumatology outpatient clinic. Annals of the Rheumatic Diseases, mars 1997; 56(3) : 188-90.
  • Hoffmann-La Roche Limitée. Monographie du Lariam®. Mississauga, Hoffmann- La Roche Limitée. 1993 (revision 2002), 14 pages.
  • Hogh B, Clarke PD, Camus D et al. Atovaquone-proguanil versus chloroquineproguanil for malaria prophylaxis in non-immune travellers : a randomised double-blind study. Lancet 2000; 356 : 1888-1894.
  • International Association for Medical Assistance to Travellers (IAMAT). How to protect yourself against malaria. Guelph, IAMAT, 2003.
  • Jong EC, Nothdurf HD. Current drugs for antimalarial chemoprophylaxis : a review of efficacy and safety. J Travel Med 2001; 8(Suppl 3) : S48-S56.
  • Kain KC, Keystone JS. Malaria in travelers : Epidemiology disease and prevention, Infectious Diseases Clinics of North America, juin 1998; 12(2) : 267-287.
  • Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001; 33 : 226-234.
  • Labbé AC et al. Recent advances in the prophylaxis and treatment of malaria. Curr Infect Dis Rep 2001; 3 : 68-76.
  • Lange WR et al. No evidence for chloroquine associated retinopathy among missionnaries on long-term malaria chemoprophylaxis. Am J Trop Med Hyg, octobre 1994; 51(4) : 389-92.
  • Lell B et al. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351 : 709-713.
  • Lell B et al. A randomized, double-blind, placebo-controlled study to evaluate the suppressive prophylactic activity of atovaquone plus proguanil (Malarone™) in children at risk of developing Plasmodium falciparum infection. Am J Trop Med Hyg 1997; 57 (S3) : S103-104, abstract no 8.
  • Lobel HO, Kozarsky PE. Update on prevention of malaria for travelers. JAMA 3 décembre 1997; 278(21) : 1767-1771.
  • MacLean JD, Demers A-M, Ndao M, Kokoskin E, Ward BJ, Gyorkos TW. Malaria epidemics and surveillance systems in Canada. Emerg Infect Dis 2004 : 10; 1195-2001.
  • Meshnick SR. Artemisinin : mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32(13) : 1655-60.
  • Ministerio de salud del Peru (Ministère de la santé du Pérou) – Direccion general de epidemiologia. Malaria general-Peru, hasta semana 24-2006. http://www.oge.sld.pe/Asis/sala/semana/malaria.pdf.
  • Nosten F. et al. Mefloquine prophylaxis prevents malaria during pregnancy : A double-blind, placebo-controlled study. J Infect Dis 1994; 169 : 595-603.
  • Ochsendorf FC, Runne U. Chloroquine : consideration of maximum daily dose (3.5mg/kg ideal body weight) prevents retinopathy. Dermatology, 1996; 192-(4) : 382-3.
  • OMS. Guidelines for the treatment of malaria. Genève, OMS, 2006.
  • OMS. International travel and health. Country list. Vaccination requirements and malaria situation. http://www.who.int/ith/countries/en/ . Accès le 11 août 2006.
  • Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC and the Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers : results from a randomised, double-blind study. Clin Infect Dis 2001; 33 : 1015-1021.
  • Phillips-Howard PA et Wood D. The safety of antimalarial drugs in pregnancy. Drug - Saf, mars 1996; 14(3) : 131-45.
  • Phillips-Howard PA, Ter-Kuile FO. CNS adverse events associated with antimalarial agents. Fact of fiction? Drug-Saf, juin 1995; 12(6) : 370-83.
  • Rynes RI. Opthalmologic considerations in using antimalarials in the United States. Lupus, juin 1996; 5 Suppl 1 : 73-4.
  • Santé Canada. Conseils de sécurité concernant l’utilisation d’insectifuges personnels. Avril 2003. http://www.hc-sc.gc.ca/francais/virus_nil/insectifuge.html.
  • Santé Canada. Recommandations canadiennes pour la prévention et le traitement du paludisme (malaria) chez les voyageurs internationaux. RMTC 2004; 30(S1) : 1-66.
  • Schlaughenhauf, P. Traveler’s malaria. Hamilton (Ontario), BC Decker, 2001.
  • Schwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malariaimplications for chemoprophylaxis in travelers. NEJM 2003; 349 : 1510-6.
  • Shanks GD. et al. Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. Med J Aust, mars 1995; 20, 162(6) : 306-7, 309-10.
  • Shanks GD et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998; 27 : 494-499.
  • Smoak BL et al. The effects of inadvertent exposure of mefloquine chimioprophylaxis on pregnancy outcomes and infants of US Army Service Women. J Infect Dis 1997; 176 : 831-3.
  • Soto J, Toledo J, Rodriquez M et al. Double-blind, randomized, placebocontrolled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. Clin Infect Dis 1999; 29 : 199-201.
  • Spalton DJ. Retinopathy and antimalarials drugs : The British experience. Lupus, juin 1996, 5 Suppl 1 : 570-2.
  • Steketee RW et al. Malaria treatment and prevention in pregnancy : indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg 1996; 55 (1 suppl) : 50-6.
  • Travel Medicine Advisor. Update on malaria, prophylaxis and treatment from the ASTMH Meeting. January/February 1998 : 3-5.
  • Van Hensbroek MB et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med, 11 juillet 1996; 335(2) : 69-75.
  • Vanhauwere B et al. Postmarketing surveillance of prophylatic mefloquine (Lariam®). Use in Pregnancy. Am J Trop Med Hyg 1998 : 17-21.
  • Van Vugt M, Ezzet E, Nosten F, Gathmann L, Wilairatana P, Looareesuwan S, White NJ. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med 1999; 61 : 964-7.
  • Weiss Walter R et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: Comparaison with mefloquine, doxycycline and chloroquine plus proguanil. J Infect Dis 1995; 171 : 1569-75.
  • Yeo AE. et Rieckmann KH. The activity of triple combinations of antifolate biguanides, with and without folinic acid, against Plasmodium falciparum in vitro. Am Trop Med Parasitol, avril 1997; 91(3) : 247-251.

Références pour la révision du février 2023 :

Références des éditions antérieures:

  • CDC. Progress toward interruption of wild poliovirus transmission-Worldwide, January 2004-March 2005. MMWR 2005; 54 : 408-412.
  • The Global Polio Eradication Initiative : http://www.polioeradication.org. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.
  • Heymann D, Aylward RB. Eradicating polio. New Engl J Med 23 sept 2004; 351(13) : 1275-1277.
  • International Travel and Health (World Health Organisation, 2017 update) : http://www.who.int/ith/2017-ith-country-list.pdf?ua=1
  • Ministère de la santé de l'Arabie Saoudite : http://www.moh.gov.sa/en/HealthAwareness/Hajj/Pages/005.aspx
  • Ministère de la santé du Japon. Poliomyelitis, Japan, 1962-1995. Infectious agents surveillance report (IASR) Jan 1997, 18(1).
  • OMS. Certification de l’éradication de la poliomyélite, région OMS du Pacifique occidental, octobre 2000. Relevé épidémiol hebdo déc 2000; 75(49) : 339-340.
  • OMS. Disease outbreak news. Archives by disease. Poliomyelitis. http://www.who.int/csr/don/archive/disease/poliomyelitis/en/  Accès le 21 juillet 2005.
  • OMS. Initiative mondiale pour l’éradication de la poliomyélite-Rapport annuel 2004. Mai 2005, WHO/Polio/05.03F
  • OMS. Fonctionnement de la surveillance de la paralysie flasque aiguë (PFA) et incidence de la poliomyélite, 1997-1998. Relevé épidémiol hebdo 1998; 73 :217-220.
  • OMS-Global polio eradication initiative. Country risk profiles. OMS, Genève, 2005. http://www.polioeradication.org/features/countryprofiles/countries.asp#B. Accès le 25 juillet 2005.
  • Sutter RW et al. Poliomyelitis eradication : progress, challenges for the end game, and preparation for the post-eradication era. Infect Dis Clin North Am 2001; 15(1) : 41-64.
  • Wood DJ, Sutter RW, Dowdle WR. Stopping poliovirus after eradication : issues and challenges. Bull OMS 2000; 78(3) : 347-363.

Références pour la mise à jour 2024

Références pour l’édition 2015 :

  • Centers for Diseases Control and Prevention (CDC). (2014). Travelers' Health - Yellow Book. Disponible sur: http://wwwnc.cdc.gov/travel/page/yellowbook-home  
  • Keystone, J.S. (2014). Travel medicine. London : Mosby Elsevier.
  • Ministère de la Santé et des Services sociaux du Québec. (2012). Guide d’intervention visant la prévention de la rage humaine. Québec: Direction des communications du ministère de la Santé et des Services sociaux.
  • Ministère de la Santé et des Services sociaux du Québec. (2009). Protocole d’immunisation du Québec, 6e édition, mises à jour 2015. Québec: Direction des communications du ministère de la Santé et des Services sociaux du Québec. Disponible sur: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/html/web/Piq.htm
  • Organisation Mondiale de la Santé. (2012). Voyages internationaux et santé, mise à jour 2014. Genève: Auteur. Disponible sur: http://www.who.int/ith/fr/  
  • Site internet : http://www.oie.int/fr/

Références des éditions antérieures :

Documents de l’Organisation mondiale de la santé et de l’Organisation panaméricaine de la santé :

Documents des Centers for Disease Control des États-Unis :

  • Allen AM et al. Schistosomes in Vietnam, Letter, Lancet June 1974; 1(7867) : 1175-1176.
  • Chitsulo L et al. The global status of schistosomiasis and its control. Act Trop 2000; 77 : 41-51.
  • CDC. Yellow Book. 2005-2006.
  • Duong TH et al. La bilharziose à S. Mekongi le long du Mekong et de ses affluents Mun et Tonle Sap. Méd tropicale1987; 47(4) : 321-328.
  • Hardalo C. Schistosomias in travelers. Travel Medicine Advisor Update, juillet août 1996.
  • Larivière M. Epidemiology of human bilharziasis. Revue du praticien 1993; 43 (4) : 417-23.
  • World Health Organization. Atlas of the global distribution of schistosomiasis. Genève. World Health Organization, 1987.
  • World Health Organization. Report of the WHO informal consultation on schistosomiasis control. Genève, World Health Organization, 1998.
  • World Health Organization. Report of the WHO informal consultation on schistosomiasis in low transmission areas : control strategies and criteria for elimination. Genève, World Health Organization, 2000.

Nouvelles références pour l’édition 2015 :

Références des éditions antérieures :

  • CCMTMV. Déclaration concernant la fièvre typhoïde et les voyages à l’étranger. RMTC 1994;20-8 : 61-68.
  • CDC. Typhoid immunization : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994;43(RR-14) : 1-7.
  • Comité consultatif national de l’immunisation (CCNI). Déclaration sur l’immunisation contre la typhoïde. Santé et Bien-Être social Canada. RMTC 1993;19(2).
  • Connor BA, Schwartz E. Typhoid and parathyphoid fever in travellers. Lancet Infect Dis 2005;5 : 623-628.
  • Crum NF. Current trends in typhoid fever. Curr Gastroenterol Rep 2003;5 : 279-286.
  • Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82 : 346-353.
  • Crump JA, Youssef FG, Luby SP et al. Estimating the incidence of typhid fecer and other febrile illnesses in developing countries. Emerg Infect Dis 2003;9 : 539-544.
  • Engels EA, Falagas ME, Lau J et al. Typhoid vaccines : a meta-analysis of studies on efficacy and toxicity. BMJ 1998;316.110-116.
  • Jelinek T et al. Risk factors for typhoid fever in travelers. J Travel Med 1996; 3(4) : 200-203.
  • Katherine J. Johnson, From the CDC: New Country-Specific Recommendations for Pre-Travel Typhoid Vaccination, Journal of Travel Medicine 2011; Volume 18 (Issue 6): 430–433
  • Keitel Wendy et al. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 1994; 12(3) : 195-199.
  • Klugman KP et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14 (5) : 435-438.
  • Kollaritsch, Herwig et al. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Inf Dis 1997; 175 : 871-5.
  • Levine MM et al. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. JAMA February 27 1991; 265(8) : 970.
  • Mathieu J et al. Typhoid fever in New York City 1980 through 1990. Arch Internal Med 1994; 154(15) : 1713-1721.
  • Mermin JH, Townes JM, Gerber M et al. Typhoid fever in the United States, 1985-1994. Arch Intern Med 1998;158 : 633-638.
  • Papadimitropoulos V, Vergidis PI, Bliziotis I et al. Vaccination against typhoid fever in travellers: a cost-effectiveness approach. Clin Microbiol Infect 2004;10 : 681-683.
  • Parry CM, Hien TT, Dougan G et al. Typhoid fever. N Engl J Med 2002;347 : 1770-1782.
  • Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vicapsular polysaccharide. Arch Intern Med 1995; 155 : 2293-2299.
  • Santé Canada. Relevé des maladies transmissibles au Canada 30 novembre 1995; 21(22) : 197-204.
  • Steinberg EB, Bishop R, Haber P et al. Typhoid fever in travelers : who should be targeted for prevention? Clin Infect Dis 2004;39 : 186-191.
  • Tacket CO, Levine MM et al. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine August 1988; 6 : 307-308.
  • Trépanier, S.; Blackburn, M.; Milord, F. (2010) Description de l’incidence et de certains facteurs de risque de la malaria, l’hépatite A, la typhoïde et la shigellose chez les voyageurs québécois. Bibliothèque du Québec et du Canada.
  • Typhoid immunization. Recommendations and reports. Morbidity and mortality weekly report December 9 1994; 43 (RR-14).
  • Viret JF, Cryz SJ Jr. Protective immunity by typhoid fever and vaccination. Vaccine 1995; 26 (Suppl 2) : 150-159.
  • Woodruff BA. A new look at typhoid vaccination : information for the practicing physician. JAMA February 13, 1991; 265 : 75-759.
  1. Organisation mondiale de la Santé (OMS). (2023). Global Tuberculosis Report 2023.  
  2. OMS. (2021). WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrugs/rifampicin-resistant TB (MDR/RR-TB), 2021-2025. 
  3. Canadian Thoracic Society. (2024). Canadian Tuberculosis Standards (8e éd. vol 8, issue sup1). Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 
  4. Diefenbach-Elstob, T. R., Alabdulkarim, B., Deb-Rinker, P. et al. (2020). Risk of latent and active tuberculosis infection in travellers: a systematic review and meta-analysis. Journal of Travel Medicine, 28(1): taaa214.
  5. Marais, B.J., Gie, R.P., Schaaf, H.S. et al. (2004). The clinical epidemiology of childhood pulmonary tuberculosis: A critical review of literature from the pre-chemotherapy era. International Journal of Tuberculosis and Lung Disease, 8(3): 278–285.  
  6. Roy, A., Eisenhut, M., Harris, R. J. et al. (2014). Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ, 349: g4643. doi:10.1136/bmj.g4643 
  7. Marais, B. J. (2011). Childhood tuberculosis: epidemiology and natural history of disease. Indian J Pediatr, 78(3): 321-7.
Dernière mise à jour :